Tae-Kyun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tae-Kyun Kim has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ichiro Nakagawa
Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan
4 shared publications - Young-Soo Park
Department of Neurosurgery, Nara Medical University, Kashihara, Japan
4 shared publications - Chul-Kee Park
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
1 shared publication Daisuke Wajima
Department of Neurosurgery, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan
1 shared publicationFumiya Sato
Department of Neurosurgery, Nara Medical University School of Medicine, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan
1 shared publication- Hiroshi Yokota
Department of Neurosurgery, Nara Prefecture General Medical Center, Nara, Japan
1 shared publication
Latest Publications
- Open Access
- 2 January 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 3
Superimposed intraoperative neuromonitoring for epidermoid cyst: Two-dimensional operative video
Background: Intraoperative neuromonitoring (IONM) is critical for preserving cranial nerve function during cerebellopontine angle (CPA) tumor surgery, particularly when multiple cranial nerves are involved. We report a case of an epidermoid cyst resection in which IONM waveforms were projected in real time onto the surgical microscope display. Case Description: A 36-year-old woman presented with the left facial spasm and numbness. Magnetic resonance imaging (MRI) revealed a left CPA lesion extending from the medulla to the midbrain, compressing the brainstem and involving cranial nerves III–XII. The tumor was removed through a lateral suboccipital approach with the patient in the park-bench position. A microscope was integrated with the neuromonitoring system. Auditory brainstem responses were used for hearing monitoring, while continuous transcranial facial motor-evoked potentials and intermittent electrical stimulation assessed facial, trigeminal, and lower cranial nerves. Real-time waveform projection onto the microscope allowed immediate recognition of signal changes during dissection. The tumor was completely removed while preserving cranial nerves III–V, VII–VIII, and lower cranial nerves. No intraoperative deterioration in waveform amplitude occurred. Postoperative MRI confirmed complete removal, and histopathology diagnosed. Facial spasm and numbness resolved without hearing loss. The patient was discharged with a modified Rankin scale score of 0 and remained symptom-free and recurrence-free at one year. Conclusion: Real-time IONM projection facilitated intraoperative communication and may contribute to safe, complete resection with cranial nerve preservation. Ethics committee approval was obtained, and the patient provided written informed consent for participation, surgical video, and publication.
- 2 January 2026
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 17, 3
Open AccessSuperimposed intraoperative neuromonitoring for epidermoid cyst: Two-dimensional operative video
Background: Intraoperative neuromonitoring (IONM) is critical for preserving cranial nerve function during cerebellopontine angle (CPA) tumor surgery, particularly when multiple cranial nerves are involved. We report a case of an epidermoid cyst resection in which IONM waveforms were projected in real time onto the surgical microscope display. Case Description: A 36-year-old woman presented with the left facial spasm and numbness. Magnetic resonance imaging (MRI) revealed a left CPA lesion extending from the medulla to the midbrain, compressing the brainstem and involving cranial nerves III–XII. The tumor was removed through a lateral suboccipital approach with the patient in the park-bench position. A microscope was integrated with the neuromonitoring system. Auditory brainstem responses were used for hearing monitoring, while continuous transcranial facial motor-evoked potentials and intermittent electrical stimulation assessed facial, trigeminal, and lower cranial nerves. Real-time waveform projection onto the microscope allowed immediate recognition of signal changes during dissection. The tumor was completely removed while preserving cranial nerves III–V, VII–VIII, and lower cranial nerves. No intraoperative deterioration in waveform amplitude occurred. Postoperative MRI confirmed complete removal, and histopathology diagnosed. Facial spasm and numbness resolved without hearing loss. The patient was discharged with a modified Rankin scale score of 0 and remained symptom-free and recurrence-free at one year. Conclusion: Real-time IONM projection facilitated intraoperative communication and may contribute to safe, complete resection with cranial nerve preservation. Ethics committee approval was obtained, and the patient provided written informed consent for participation, surgical video, and publication.
- Open Access
- 1 May 2025
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (3) , 272-277
Clinical and Genetic Overview of Neurofibromatosis Type 2 (NF2)
Neurofibromatosis type 2 (NF2) is an autosomal dominant disease characterized by bilateral vestibular schwannomas and other central nervous tumors such as meningiomas and spinal ependymomas. Symptoms vary according to the age at diagnosis and the location of these tumors. The diagnostic criteria of NF2 have been regularly revised and recently updated in 2022 with a new nomenclature “NF2-related schwannomatosis” to differentiate NF2 from other schwannoma predisposing disorders, such as SMARCB1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1)-, LZTR1 (leucine zipper-like transcription regulator 1)-, and 22q-related schwannomatosis. Addition to the clinical features, genetic testing for pathogenic variants in these genes became an important essence to support diagnosis of NF2 and other schwannomatosis, including mosaic conditions.
- 1 May 2025
- Published by Korean Neurosurgical Society in Journal of Korean Neurosurgical Society
- Vol. 68 (3) , 272-277
Open AccessClinical and Genetic Overview of Neurofibromatosis Type 2 (NF2)
Neurofibromatosis type 2 (NF2) is an autosomal dominant disease characterized by bilateral vestibular schwannomas and other central nervous tumors such as meningiomas and spinal ependymomas. Symptoms vary according to the age at diagnosis and the location of these tumors. The diagnostic criteria of NF2 have been regularly revised and recently updated in 2022 with a new nomenclature “NF2-related schwannomatosis” to differentiate NF2 from other schwannoma predisposing disorders, such as SMARCB1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1)-, LZTR1 (leucine zipper-like transcription regulator 1)-, and 22q-related schwannomatosis. Addition to the clinical features, genetic testing for pathogenic variants in these genes became an important essence to support diagnosis of NF2 and other schwannomatosis, including mosaic conditions.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (18) , e62
Radiation-Induced Meningiomas Have an Aggressive Clinical Course: Genetic Signature Is Limited to NF2 Alterations, and Epigenetic Signature Is H3K27me3 Loss
Kim TK, et al. J Korean Med Sci. 2025 Jan;40:e62. https://doi.org/10.3346/jkms.2025.40.e62
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (18) , e62
Open AccessRadiation-Induced Meningiomas Have an Aggressive Clinical Course: Genetic Signature Is Limited to NF2 Alterations, and Epigenetic Signature Is H3K27me3 Loss
Kim TK, et al. J Korean Med Sci. 2025 Jan;40:e62. https://doi.org/10.3346/jkms.2025.40.e62
- Open Access
- 10 February 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 14, 202-209
Neuroprotective effects of pravastatin in cerebral venous infarction in a rat model
- 10 February 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 14, 202-209
Open AccessNeuroprotective effects of pravastatin in cerebral venous infarction in a rat model
- 13 July 2020
- Published by Springer Nature in Child's Nervous System
- Vol. 37 (1) , 69-79
Efficacy and safety of intraventricular fibrinolytic therapy for post-intraventricular hemorrhagic hydrocephalus in extreme low birth weight infants: a preliminary clinical study
Purpose To evaluate the efficacy and safety of our unique therapy for treating post-intraventricular hemorrhagic hydrocephalus (PIVHH) in low birth weight infants (LBWls) through an early stage fibrinolytic therapeutic strategy involving urokinase (UK) injection into the lateral ventricle, called the “Ventricular Lavage (VL) therapy.” Methods Overall, 43 consecutive infants with PIVHH were included. Most were extremely LBWIs (n = 39). Other cases included very LBWIs (n = 2) and full-term infants (n = 2). VL therapy involved continuous external ventricular drainage (EVD) management using a very fine catheter and intermittent slow injection of 6000 IU of UK every 3–6 h to actively dissolve hematomas. Results Early EVD management (within 3 weeks of IVH onset) was performed in 25 infants, with combination VL therapy in 21 infants. Five initiated late EVD management (≥ 3 weeks after IVH onset); the remaining 13 were treated conservatively for several weeks, delaying surgical intervention. Eighteen of 21 (86%) infants who received VL therapy did not require permanent shunt surgery. There were no serious complications, including the absence of secondary hemorrhage and infection. Two-thirds of the infants treated in the late stages required permanent shunt, and various shunt-related complications frequently occurred. A good outcome occurred in 13/17 infants in the early treatment group, despite most subjects having an IVH grade IV, and in 6/15 in the late treatment group. Conclusions Permanent shunt surgery needs were dramatically reduced following early VL therapy, and functional outcomes were favorable. VL therapy might be a promising strategy that could lead to the development of new treatments for PIVHH.
- 13 July 2020
- Published by Springer Nature in Child's Nervous System
- Vol. 37 (1) , 69-79
Efficacy and safety of intraventricular fibrinolytic therapy for post-intraventricular hemorrhagic hydrocephalus in extreme low birth weight infants: a preliminary clinical study
Purpose To evaluate the efficacy and safety of our unique therapy for treating post-intraventricular hemorrhagic hydrocephalus (PIVHH) in low birth weight infants (LBWls) through an early stage fibrinolytic therapeutic strategy involving urokinase (UK) injection into the lateral ventricle, called the “Ventricular Lavage (VL) therapy.” Methods Overall, 43 consecutive infants with PIVHH were included. Most were extremely LBWIs (n = 39). Other cases included very LBWIs (n = 2) and full-term infants (n = 2). VL therapy involved continuous external ventricular drainage (EVD) management using a very fine catheter and intermittent slow injection of 6000 IU of UK every 3–6 h to actively dissolve hematomas. Results Early EVD management (within 3 weeks of IVH onset) was performed in 25 infants, with combination VL therapy in 21 infants. Five initiated late EVD management (≥ 3 weeks after IVH onset); the remaining 13 were treated conservatively for several weeks, delaying surgical intervention. Eighteen of 21 (86%) infants who received VL therapy did not require permanent shunt surgery. There were no serious complications, including the absence of secondary hemorrhage and infection. Two-thirds of the infants treated in the late stages required permanent shunt, and various shunt-related complications frequently occurred. A good outcome occurred in 13/17 infants in the early treatment group, despite most subjects having an IVH grade IV, and in 6/15 in the late treatment group. Conclusions Permanent shunt surgery needs were dramatically reduced following early VL therapy, and functional outcomes were favorable. VL therapy might be a promising strategy that could lead to the development of new treatments for PIVHH.